Search Results 241-250 of 7748 for Fungicides
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary ...
This study is to see if PCR test developed at Mayo Clinic to diagnosis C. Difficile infections is able to predict the risk of recurrent infection. Participation ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Cediranib maleate and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the ...
Mayo Clinic's Infectious Diseases Laboratory, led by Robin Patel, M.D., investigates antimicrobial agents to combat multidrug-resistant bacteria.
The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or ...
Radiologists at Mayo Clinic were instrumental in developing novel bowel imaging techniques, including magnetic resonance (MR) and CT enterography. Current ...
About this study. A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to ...
Monoclonal antibodies, such as anetumab ravtansine and atezolizumab, may interfere with the ability of tumor cells to grow and spread. Participation eligibility.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.